Boehringer's Ofev wins green light in Europe; Wales grants access to Ariad's Iclusig;

> SCIO Health Analytics has picked up Data Intelligence, a business intelligence and analytics provider to the pharma industry. News

> A panel from the U.K.'s Prescription Medicines Code of Practice Authority (PMCPA) has ruled out a complaint from a pharmacist that the artwork image for Boehringer Ingelheim's COPD drug Striverdi is misleading. More

> Boehringer Ingelheim's Ofev has won European approval as a treatment for idiopathic pulmonary fibrosis. Report

> Wales is providing access to Ariad Pharmaceutical's ($ARIA) Iclusig on its National Health Service. More

> BMG Pharma has signed an exclusive distribution agreement with Ferrer Internacional, granting it the rights to promote, sell and market its GelX for the Middle East, Eastern Europe, Russia and North Africa. Release

And Finally... The FDA has clarified the lines between wellness devices and regulated medical devices. More

Suggested Articles

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Call it a fall sports bounce. TV ad spending bumped up in August with the partial return of professional sports, and that included pharma buyers.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.